Follow
Subscribe to eleva GmbH

eleva GmbH

Filter
  • 12.10.2021 – 10:30

    Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins

    Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production ...

  • 14.09.2021 – 10:30

    Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H

    Freiburg (ots) - Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-art, 500 l single-use reactors from Sartorius Stedim Systems. The scale-up will enable Eleva to enter ...

  • 06.01.2021 – 10:00

    Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

    Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...

  • 03.06.2020 – 10:00

    Eleva's drug candidate to be examined for use in Covid-19 treatment

    Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...